[go: up one dir, main page]

MX2010005055A - Modulacion de la expresion del factor 7. - Google Patents

Modulacion de la expresion del factor 7.

Info

Publication number
MX2010005055A
MX2010005055A MX2010005055A MX2010005055A MX2010005055A MX 2010005055 A MX2010005055 A MX 2010005055A MX 2010005055 A MX2010005055 A MX 2010005055A MX 2010005055 A MX2010005055 A MX 2010005055A MX 2010005055 A MX2010005055 A MX 2010005055A
Authority
MX
Mexico
Prior art keywords
factor
antisense compounds
modulation
expression
embolism
Prior art date
Application number
MX2010005055A
Other languages
English (en)
Inventor
Hong Zhang
Susan M Freier
Brett P Monia
Jeffrey R Crosby
Chenguang Zhao
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of MX2010005055A publication Critical patent/MX2010005055A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen en la presente compuestos de antisentido y métodos para disminuir el Factor 7 y para tratar o prevenir complicaciones tromboembólicas, trastornos hiperproliferativos o condiciones inflamatorias en un individuo con necesidad de los mismos. Ejemplos de condiciones de enfermedad que pueden mejorar con la administración de los compuestos de antisentido dirigidos al Factor 7 incluyen trombosis, embolia y tromboembolia, tal como la trombosis de vena profunda, embolia pulmonar, infarto al miocardio, accidente cerebrovascular, cáncer, artritis reumatoide y fibrosis.
MX2010005055A 2007-11-09 2008-11-05 Modulacion de la expresion del factor 7. MX2010005055A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98692807P 2007-11-09 2007-11-09
PCT/US2008/082526 WO2009061851A2 (en) 2007-11-09 2008-11-05 Modulation of factor 7 expression

Publications (1)

Publication Number Publication Date
MX2010005055A true MX2010005055A (es) 2010-06-25

Family

ID=40417602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005055A MX2010005055A (es) 2007-11-09 2008-11-05 Modulacion de la expresion del factor 7.

Country Status (13)

Country Link
US (1) US9029337B2 (es)
EP (2) EP3000884B1 (es)
JP (1) JP2011502514A (es)
KR (1) KR20100105550A (es)
CN (1) CN102076852A (es)
AU (1) AU2008323970B2 (es)
BR (1) BRPI0820391A2 (es)
CA (1) CA2705316A1 (es)
IL (1) IL205536A0 (es)
MX (1) MX2010005055A (es)
NZ (1) NZ585250A (es)
RU (1) RU2010119775A (es)
WO (1) WO2009061851A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2454369A4 (en) * 2009-07-16 2013-07-03 Isis Pharmaceuticals Inc MODULATION OF FACTOR 7 EXPRESSION
WO2011123394A1 (en) * 2010-03-31 2011-10-06 Isis Pharmaceuticals, Inc. Modulation of matrix metalloproteinase 13 (mmp-13) expression
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2638163B1 (en) 2010-11-12 2017-05-17 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2012087983A1 (en) * 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding rnas
AU2011349464B2 (en) * 2010-12-20 2016-07-07 The General Hospital Corporation Polycomb-associated non-coding RNAS
WO2012109395A1 (en) 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012174154A1 (en) * 2011-06-13 2012-12-20 Isis Pharmaceuticals, Inc. Modulation of inflammatory responses by factor vii
EP3205725B1 (en) 2011-08-11 2019-03-27 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US8865674B2 (en) * 2011-09-20 2014-10-21 Isis Pharmaceuticals, Inc. Antisense modulation of GCGR expression
US20140378533A1 (en) * 2012-02-08 2014-12-25 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
WO2013119979A1 (en) * 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Methods and compositions for modulating factor vii expression
AU2013202595B2 (en) 2012-03-30 2016-04-21 Biogen Ma Inc. Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013159108A2 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2013173638A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating smn gene family expression
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
BR112014028631A2 (pt) 2012-05-16 2017-10-17 Rana Therapeutics Inc composições e métodos para modulação da expressão da família de genes da hemoglobina
KR20160074368A (ko) 2012-05-16 2016-06-28 라나 테라퓨틱스, 인크. Utrn 발현을 조절하기 위한 조성물 및 방법
EA201492120A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии atp2a2
US9695418B2 (en) 2012-10-11 2017-07-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
US20150275208A1 (en) 2012-10-12 2015-10-01 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
RU2730677C2 (ru) * 2012-10-15 2020-08-24 Ионис Фармасьютикалз, Инк. Соединение для модуляции экспрессии гена c9orf72 и его применение
MX2015009056A (es) 2013-01-30 2015-10-05 Hoffmann La Roche Conjugados de oligonucleotidos de acido nucleico bloqueado y carbohidratos.
BR112015027322A8 (pt) 2013-05-01 2018-01-02 Isis Pharmaceuticals Inc Compostos antissenso conjugados e sua utilização
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
CA2924277A1 (en) * 2013-10-18 2015-04-23 Institut De Cardiologie De Montreal Genotyping tests and methods for evaluating plasma creatine kinase levels
BR122020024446B8 (pt) 2014-05-01 2022-06-28 Ionis Pharmaceuticals Inc Compostos para modulação da expressão do receptor do hormônio de crescimento
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
WO2016138353A1 (en) 2015-02-26 2016-09-01 Ionis Pharmaceuticals, Inc. Allele specific modulators of p23h rhodopsin
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
CN109661233A (zh) 2016-10-06 2019-04-19 Ionis 制药公司 缀合低聚化合物的方法
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6001992A (en) * 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US6180403B1 (en) 1999-10-28 2001-01-30 Isis Pharmaceuticals Inc. Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US20030228597A1 (en) * 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
EP1499627A2 (en) 2001-07-03 2005-01-26 ISIS Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20030087244A1 (en) * 2001-10-09 2003-05-08 Vitivity, Inc Diagnosis and treatment of vascular disease
ES2226533B1 (es) * 2002-07-25 2005-12-16 Fundacio Privada I Institut De Recerca De L'hospital De La Santa Creu I Sant Pau Nuevas variantes alelicas en el gen del factor vii.
EP1578927A2 (en) 2002-08-14 2005-09-28 Pharmacia Corporation Antisense modulation of nav1.3 expression
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2213738B1 (en) 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
WO2004092325A2 (en) * 2002-12-24 2004-10-28 Board Of Regents, The University Of Texas System Screening methods using zebrafish to identify thrombotic and anti-thrombotic compounds and genes
US7202264B2 (en) * 2003-01-31 2007-04-10 Isis Pharmaceuticals, Inc. Supports for oligomer synthesis
WO2004094636A1 (en) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2006020768A2 (en) * 2004-08-10 2006-02-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
CN101098755B (zh) 2005-01-14 2010-06-09 陶氏环球技术公司 钛硅酸盐的回收和活性氧化催化剂的再生
EP1984381B1 (en) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
US20080068922A1 (en) 2006-09-12 2008-03-20 Voss Klaus-W Device for blending a binder component and a hardener component for producing a ready-made filler
JP2008068470A (ja) 2006-09-13 2008-03-27 Kyocera Mita Corp 電子機器、ジョブデータ認証受信プログラム
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
US8389488B2 (en) * 2007-11-05 2013-03-05 Isis Pharmaceuticals, Inc. Antidotes to antisense compounds
EP2848688A1 (en) * 2007-12-10 2015-03-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor VII gene
CA2743249A1 (en) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of factor vii genes

Also Published As

Publication number Publication date
NZ585250A (en) 2012-06-29
WO2009061851A2 (en) 2009-05-14
WO2009061851A3 (en) 2009-07-16
BRPI0820391A2 (pt) 2015-05-19
RU2010119775A (ru) 2011-12-27
US20100298417A1 (en) 2010-11-25
JP2011502514A (ja) 2011-01-27
EP3000884A1 (en) 2016-03-30
AU2008323970A1 (en) 2009-05-14
EP3000884B1 (en) 2018-09-12
KR20100105550A (ko) 2010-09-29
CA2705316A1 (en) 2009-05-14
EP2227545A2 (en) 2010-09-15
IL205536A0 (en) 2010-12-30
AU2008323970B2 (en) 2014-05-08
US9029337B2 (en) 2015-05-12
CN102076852A (zh) 2011-05-25

Similar Documents

Publication Publication Date Title
MX2010005055A (es) Modulacion de la expresion del factor 7.
WO2010045509A3 (en) Modulation of factor 11 expression
WO2017062816A8 (en) Compounds and methods for modulating angiotensinogen expression
WO2010121074A8 (en) Modulation of inflammatory responses by factor xi
WO2014179626A3 (en) Compositions and methods for modulating apolipoprotein c-iii expression
HK1249140A1 (zh) 用於调节tmprss6表达的化合物和方法
MX2012002269A (es) Metodos y composiciones para el tratamiento de trastornos fibroticos pulmonares.
WO2009045370A3 (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
MX373898B (es) Composiciones y métodos para la expresión de arns guías de crispr que usando el promotor h1.
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
IN2012DN01572A (es)
WO2009011850A3 (en) Novel therapeutic compounds
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
EP2602314A4 (en) MUTANT MICROORGANISM WITH HIGH PRODUCTION OF CADAVERIN AND METHOD FOR PRODUCING CADAVERIN THEREWITH
PH12017501758A1 (en) Heterocyclymethyl-thienouracile as antagonists of the adenosine-a2b-receptor
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
MY170980A (en) Thrombin-binding antibody molecules and uses thereof
NZ605022A (en) Heterocyclic compounds, their preparation and their therapeutic application
ZA201402795B (en) 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
MX2023014444A (es) Modular la expresion de apolipoproteina (a).
WO2012064758A3 (en) Methods for modulating factor 12 expression
WO2009061852A3 (en) Modulation of factor 9 expression
EP1865778A4 (en) METHOD FOR AVOIDING OEDEM IN THE TREATMENT OF METABOLISM DISORDER, INFLAMMATORY DISEASES AND CARDIOVASCULAR DISEASES
MX337051B (es) Tratamiento de inflamacion cronica con un derivado de 1, 2, 4-triazolo [1,5a] piridina.
WO2014195500A3 (de) Lageranordnung und verfahren zum herstellen einer lageranordnung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal